摘要
背景:最近的研究评估了循环肿瘤DNA(CTDNA)分析在检测NSCLC患者血浆表皮生长因子受体(EGFR)突变中的诊断准确性,总体上显示出与标准组织基因分型的高度一致性。然而,如果转移部位的位置可能影响识别EGFR突变的能力尚不清楚。 目的:本研究旨在评估转移位点的位置与CTNC分析对检测NSCLC患者EGFR突变的敏感性之间的关系。 方法:通过PubMed、Cochrane图书馆、美国临床肿瘤学协会和世界肺癌会议会议录,收集所有发表的研究,评估基于血浆的EGFRAMP测试的敏感性,通过转移部位定位(胸外(M1B)和胸内(M1A))分层肺癌的发病情况。根据转移位点的位置,计算cDNA分析灵敏度的混合比值(OR)和95%置信区间(95%顺式)。 结果:共有十项研究,其中1425例符合条件。汇总分析表明,CT1DNA的EGFR突变检测的敏感性在M1B与M1A疾病(OR:5.09;95% CIS:2.93–8.84)的患者中显著增高。EGFR激活(OR:4.30,95% CI:2.35-7.88)和抗性T790M突变(OR:11.89,95% CI:1.45-97.22),无论使用数字PCR(OR:5.85,95% CI:3.55-960)或非数字PCR技术(OR:2.96,95% CI:2.24~3.91),均观察到显著的关联。 结论:这些数据表明,转移位点的位置显著影响CTNC分析在检测NSCLC患者EGFR突变中的诊断准确性。
关键词: 表皮生长因子受体,ctDNA,液体活检,非小细胞(型)肺癌,转移部位,胸内,胸外。
图形摘要
Current Cancer Drug Targets
Title:Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis
Volume: 18 Issue: 7
关键词: 表皮生长因子受体,ctDNA,液体活检,非小细胞(型)肺癌,转移部位,胸内,胸外。
摘要: Background: Recent studies evaluated the diagnostic accuracy of circulating tumor DNA (ctDNA) analysis in the detection of epidermal growth factor receptor (EGFR) mutations from plasma of NSCLC patients, overall showing a high concordance as compared to standard tissue genotyping. However it is less clear if the location of metastatic site may influence the ability to identify EGFR mutations.
Objective: This pooled analysis aims to evaluate the association between the metastatic site location and the sensitivity of ctDNA analysis in detecting EGFR mutations in NSCLC patients.
Methods: Data from all published studies, evaluating the sensitivity of plasma-based EGFRmutation testing, stratified by metastatic site location (extrathoracic (M1b) vs intrathoracic (M1a)) were collected by searching in PubMed, Cochrane Library, American Society of Clinical Oncology, and World Conference of Lung Cancer, meeting proceedings. Pooled Odds ratio (OR) and 95% confidence intervals (95% CIs) were calculated for the ctDNA analysis sensitivity, according to metastatic site location.
Results: A total of ten studies, with 1425 patients, were eligible. Pooled analysis showed that the sensitivity of ctDNA-based EGFR-mutation testing is significantly higher in patients with M1b vs M1a disease (OR: 5.09; 95% CIs: 2.93 – 8.84). A significant association was observed for both EGFR-activating (OR: 4.30, 95% CI: 2.35-7.88) and resistant T790M mutations (OR: 11.89, 95% CI: 1.45-97.22), regardless of the use of digital-PCR (OR: 5.85, 95% CI: 3.56-9.60) or non-digital PCR technologies (OR: 2.96, 95% CI: 2.24-3.91).
Conclusions: These data suggest that the location of metastatic sites significantly influences the diagnostic accuracy of ctDNA analysis in detecting EGFR mutations in NSCLC patients.
Export Options
About this article
Cite this article as:
Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis, Current Cancer Drug Targets 2018; 18 (7) . https://dx.doi.org/10.2174/1568009618666180308125110
DOI https://dx.doi.org/10.2174/1568009618666180308125110 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genomic Sequence Analysis of EGFR Regulation by MicroRNAs in Lung Cancer
Current Topics in Medicinal Chemistry Plasma-Rich in Growth Factor and its Clinical Application
Current Stem Cell Research & Therapy Update on MDS Therapy: From Famine to Feast
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting of Cancer-Related Proteins with PNA Oligomers
Current Cancer Drug Targets Raman Molecular Imaging of Cells and Tissues: Towards Functional Diagnostic Imaging Without Labeling
Current Pharmaceutical Biotechnology Anticancer Agent Ukrain and Bortezomib Combination is Synergistic in 4T1 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Pharmacological and Clinical Studies on Purine Nucleoside Analogs- New Anticancer Agents
Mini-Reviews in Medicinal Chemistry Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry Update on Hsp90 Inhibitors in Clinical Trial
Current Topics in Medicinal Chemistry FDG-PET in Tuberculosis
Current Molecular Imaging (Discontinued) Protein Kinases as Drug Targets in Cancer
Current Cancer Drug Targets Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery
Current Medicinal Chemistry Intracellular Routing of Cytotoxic Pancreatic-Type Ribonucleases
Current Pharmaceutical Biotechnology MicroRNAs in Genetic Disease: Rethinking the Dosage
Current Gene Therapy Design of Fucoidan Functionalized - Iron Oxide Nanoparticles for Biomedical Applications
Current Drug Delivery Chemical Constituents of the Genus Prunus and their Medicinal Properties
Current Medicinal Chemistry Carotenoids and Modulation of Cancer: Molecular Targets
Current Pharmacogenomics Overcoming the Hurdles of Tumor Immunity by Targeting Regulatory Pathways in Innate and Adaptive Immune Cells
Current Pharmaceutical Design 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity
Anti-Cancer Agents in Medicinal Chemistry Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene
Current Cancer Therapy Reviews